Published in final edited form as:

Psychopharmacology (Berl). 2019 February ; 236(2): 581–590. doi:10.1007/s00213-018-5083-5.

Lack of consistent sex differences in d-amphetamine-induced dopamine release measured with [¹⁸F]fallypride PET

Christopher T. Smith, Ph.D.^{1,*}, Linh C. Dang, Ph.D.¹, Leah L. Burgess¹, Scott F. Perkins, M.A.¹, M. Danica San Juan, M.S.¹, Darcy K. Smith, M.Ed.¹, Ronald L. Cowan, M.D., Ph.D.^{1,2,3}, Nam T. Le, M.D.³, Robert M. Kessler, M.D.⁴, Gregory R. Samanez-Larkin, Ph.D.⁵, and David H. Zald, Ph.D.^{1,2}

¹Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817

²Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Suite 3057, Nashville, TN, 37212

³Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Medical Center North, 1161 21st Ave. South, Nashville, TN 37232 USA

⁴Department of Radiology, UAB School of Medicine, 1802 6th Ave South, Birmingham, AL 35233

⁵Department of Psychology and Neuroscience, Duke University, 417 Chapel Drive, Durham, NC 27708

Abstract

Rationale: Sex differences in the dopaminergic response to psychostimulants could have implications for drug abuse risk and other psychopathology involving the dopamine system, but human data are limited and mixed.

Objectives: Here, we sought to investigate sex differences in dopamine release after oral d-amphetamine administration.

Methods: We used [¹⁸F]fallypride Positron Emission Tomography (PET) to measure the change in dopamine D2/3 receptor availability (% BP_{ND}, an index of dopamine release) between placebo and d-amphetamine sessions in two independent datasets containing a total of 39 females (either on hormonal birth control n=18, postmenopausal n=10, or studied in the first 10 days of their menstrual cycle n=11) and 37 males.

Results: Using both *a priori* anatomical regions of interest based on previous findings as well as voxelwise analyses, we failed to consistently detect broad sex differences in d-amphetamine-induced dopamine release. Nevertheless, there was limited evidence for greater right ventral striatal dopamine release in young adult males relative to similarly aged females, but this was not

*Corresponding Author: christopher.t.smith@vanderbilt.edu.

Conflict of Interest Statement

On behalf of all authors, the corresponding author states that there is no conflict of interest or competing financial interests in relation to the work described.

consistently observed across samples. Plasma estradiol did not correlate with dopamine release and this measure did not differ in females on and off hormonal birth control.

Conclusions: While our finding in young adults from one dataset of greater % BP_{ND} in males is partially consistent with a previously published study on sex differences in d-amphetamine-induced dopamine release, our data do not support the presence of *consistent widespread* sex differences in this measure of dopamine release.

Keywords

sex differences; dopamine; PET; D2/3 receptor availability; dopamine release; d-amphetamine

Introduction

Women and men differ in the symptom expression, onset, and prevalence of psychopathology (Dohrenwend and Dohrenwend 1976; Earls 1987; Seeman 1997). In the context of addiction, differences have been observed in female versus male responses to psychostimulants and drug-associated cues. Female rats acquire cocaine self-administration more readily (Lynch and Carroll 1999) and display increased motivation (higher breakpoints on a progressive ratio schedule) to self-administer intravenous cocaine than males (Lynch 2008; Roberts et al. 1989). Furthermore, cocaine self administration varies across the estrous cycle in female rodents (Lynch et al. 2000). Serum estradiol correlates with the amount of cocaine self-administered (Lynch 2008), and estradiol increases both cocaine-self administration (Jackson et al. 2006; Lynch et al. 2001) and extracellular dopamine levels (Cummings et al. 2014) in ovariectomized female rats (Jackson et al. 2006; Lynch et al. 2001).

Furthermore, estradiol has been shown to increase striatal dopamine synthesis (Pasqualini et al. 1995), levels of tyrosine hydroxylase (Ivanova and Beyer 2003), and basal dopamine neuron activity in the ventral tegmental area (VTA) (Calipari et al. 2017). A recent study by Calipari et al also found that estradiol increases post translational modifications of the dopamine transporter (DAT) which ultimately increase cocaine's ability to inhibit DAT's function (Calipari et al. 2017). The authors go on to demonstrate that these estradiol-mediated modification of DAT lead to increased cocaine conditioned place preference (Calipari et al. 2017).

These preclinical data suggest that sex differences may exist in response to psychostimulant drugs (which act on DAT) in humans. Indeed, although overall rates of addiction are higher in men, cocaine-dependent women have been shown to have more severe drug-related problems at intake (Griffin et al. 1989; Kosten et al. 1993) and greater drug craving to cocaine cues than men (Robbins et al. 1999). Furthermore, estrogen and progesterone have been shown to affect the subjective responses of euphoria to, liking of, and wanting of oral d-amphetamine (dAMPH) in human subjects (Justice and de Wit 1999; White et al. 2002). In addition, subjective ratings of cocaine in cocaine-smoking women vary over the menstrual cycle (Evans et al. 2002).

Amphetamine-induced dopamine release is also potentiated by estradiol in rodents (Becker 1990; 1999). Two human PET studies have investigated differences in dAMPH induced dopamine release as a function of participant sex (Munro et al. 2006; Riccardi et al. 2006). Munro et al (2006) found that young adult (aged 18–29) men (n=28) displayed heightened striatal dopamine release measured with ^{11}C -raclopride compared to women (n=15). Using [^{18}F]fallypride, Riccardi et al (2006) found young adult women (n=6; aged 21–29) displayed greater dopamine release in right globus pallidus and inferior frontal gyrus compared to men (n=7). Given the small sample sizes in these PET studies, it is critical to evaluate potential sex differences with larger sample sizes, especially when existing findings from smaller sample studies have conflicted.

Here, we assessed sex differences in dAMPH-induced dopamine release across two separate studies using [^{18}F]fallypride PET to evaluate the reliability of potential sex effects in independent datasets.

Materials and Methods

Participants and Procedure

All participants were recruited from the Nashville, TN, metropolitan area using a combination of print, radio, and online advertisements and completed written informed consent approved by the Vanderbilt University Institutional Review Board. Exclusion criteria included any axis-1 psychiatric disorder, use of psychoactive drugs, illicit drug use, and alcohol consumption greater than ~5 standard alcoholic drinks/week. Furthermore, >3 lifetime stimulant use episodes was exclusionary for study inclusion. All participants underwent a structured clinical interview (First et al. 2002) for these exclusionary criteria in addition to a medical physical (with EKG), a complete blood count panel, and structural MR scans (T1 and T2-FLAIR weighted) to exclude pathology. All female participants were either postmenopausal (Dataset 2: n=10), on hormonal birth control (Dataset 1: n=11; Dataset 2: n=6 Young Adults, 4 on birth control pill, 2 on Mirena IUD; n=1 Middle-aged Adult using birth control as hormone replacement therapy) or naturally cycling (Dataset 1: n=7; Dataset 2: n=4 Young Adults), in which case they completed both PET scans within the first 10 days of their menstrual cycle.

Dataset 1 consisted of previously published dopamine release data (Buckholtz et al. 2010; Samanez-Larkin et al. 2013; Smith et al. 2016a) from 18 females (age=22.9±3.0) and 16 males (age=21.8±3.2). Dataset 1 scan order was fixed as 1) Placebo, 2) dAMPH, with participants blind to drug administration order. Dataset 2 consists of data from a current study investigating adult age effects on dopamine signaling recruiting participants aged 20–30 (young adults, YA) and 50–65 (middle-aged adults, MA). The analyzed data consisted of 21 females (10 YA, 11 MA; age=40.2±3.3) and 21 males (10 YA, 11 MA) age=42.48±3.4). In dataset 2 drug order was randomized with participants blind to administration on each visit; 42.9% of males and 52.4% of females received dAMPH on their first visit. Drug (or placebo) was administered orally (dAMPH dose: 0.43 mg/kg) three hours prior to the [^{18}F]fallypride PET scan in both datasets. We have previously shown that blood levels of amphetamine peak by 3 hours post oral dAMPH (Smith et al. 2016b) administration and remain elevated for several hours after reaching peak. Blood draws for female hormone

(estradiol) analysis were performed on both placebo and dAMPH day in Dataset 1 and only on dAMPH day in Dataset 2. These blood draws were taken just prior to the placebo or dAMPH administration.

PET Data Acquisition

[¹⁸F]fallypride ((S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3[¹⁸F]fluoropropyl)-2,3-dimethoxybenzamide) was produced in the radiochemistry laboratory attached to the PET unit, following synthesis and quality control procedures described in US Food and Drug Administration IND 47,245.

Serial scan acquisition was started simultaneously with a 5.0 mCi (185 MBq) slow bolus injection (duration ~10 sec) of DA D2/3 tracer [¹⁸F]fallypride (specific activity > 3000 Ci/mmol). CT scans were collected for attenuation correction prior to each of the three emission scans (of lengths 68.5 minutes, 50 minutes, and 60 minutes), which together lasted approximately 3.5 hours, including time for two breaks between each scan for subject comfort. The specific acquisition timing of the dynamic data for each Dataset can be found in Supplementary Table 1. The only difference in data acquisition across datasets was the number of frames acquired in the last two emission scans (which were the same total duration across datasets): second emission scan lasted 3000 seconds (with 2 1500-sec length frames in Dataset 1 and 4 750-sec length frames in Dataset 2) followed by a second break and then a third emission scan acquisition lasting 3600 seconds (with 2 1800-sec length frames in Dataset 1 and 3 900-sec length frames in Dataset 2). [¹⁸F]fallypride PET signal reliably reaches equilibrium in the striatum within 3 hours (Vernaleken et al. 2011), making our acquisition parameters more than sufficient to capture this equilibrium state, a key requirement for estimating BP_{ND}. Importantly, PET data reported from both studies were collected on the same GE Discovery STE scanner.

PET Data Processing

After decay correction and attenuation correction, PET scan frames were corrected for motion using SPM8 (Friston et al. 1995) with the last dynamic image frame of the first series serving as the reference image. The mean PET image created from the realignment was then registered to each subject's high-resolution T1 MRI image (FLIRT, 6 degrees of freedom), which was nonlinearly registered to MNI space (FNIRT) in FSL (Smith et al. 2004). Putamen and cerebellum reference regions of interest (ROIs) were created from the WFU Pickatlas (Maldjian et al. 2003) with the cerebellum modified such that the anterior ¼ of the ROI along with voxels within 5mm of cortex were excluded to prevent contamination of the PET signal from nearby areas such as midbrain or occipital cortex. These ROIs were then warped to each subject's PET space using the FLIRT and FNIRT FSL transform matrices (MNI→T1→PET) and used in a simplified reference tissue model (SRTM(Lammertsma and Hume 1996)) performed in PMOD software (PMOD Technologies, Zurich Switzerland) to estimate [¹⁸F]fallypride binding potential (BP_{ND}, a ratio of specifically bound [¹⁸F]fallypride to its non-displaceable concentration). Specifically, PMOD's PXMOT tool was used to estimate BP_{ND} voxel-wise using a published basis function fitting approach (Gunn et al. 1997). PXMOT uses time-activity curves extracted from the putamen and cerebellum from each subject to optimize the initial

conditions for estimation of BP_{ND} with SRTM. The cerebellum data served as the input function to the model.

The resulting BP_{ND} maps for placebo and dAMPH days were then warped to MNI space using the saved FSL transforms to create MNI-normalized BP_{ND} images (resampled to 2 mm isotropic voxels). We also created % BP_{ND} images by linearly registering the placebo and dAMPH BP_{ND} maps to one another (FLIRT, 6 degrees of freedom) and the difference in BP_{ND} maps (% BP_{ND}) after dAMPH was calculated as:

$$\% \Delta BP_{ND} = (\text{placebo } BP_{ND} - \text{dAMPH } BP_{ND}) / (\text{placebo } BP_{ND}) \times 100\%$$

Thus, an increase in % BP_{ND} corresponded to an increase in synaptic DA release. Subject-specific % BP_{ND} images were also warped to MNI space using the saved FSL transforms to create MNI-normalized % BP_{ND} images (resampled to 2 mm isotropic voxels). These MNI-normalized images were then analyzed (using an explicit MNI brain mask) in SPM8 to test for sex differences in drug effects on BP_{ND} .

A priori anatomical regions of interest

Based on previous findings of sex differences in dAMPH-induced DA release (Munro et al. 2006; Riccardi et al. 2006), we focused on 5 anatomical ROIs. For each subject we extracted each ROI's BP_{ND} value as the average value from the subject's PXM0D-generated SRTM BP_{ND} map, warped to MNI standard space. The *a priori* ROIs from which we extracted data included the right AAL atlas (Tzourio-Mazoyer et al. 2002) pallidum and inferior (opercular) frontal gyrus (IFG). In addition, we investigated bilateral striatal ROIs [ventral striatum (VS), caudate, and putamen] as defined in Mawlawi et al (Mawlawi et al. 2001) and used previously in our research group (Smith et al. 2017). These ROIs are depicted on a template MNI brain in Supplementary Figure 1.

Data Analysis

Taking a whole-brain approach, our main voxelwise analyses focused on testing for a dAMPH effect and then a Sex $\times$ dAMPH effect on BP_{ND} via flexible factorial design implemented in SPM8. Within each dataset in SPM8, we first modeled the effect of Sex group and Drug type (placebo, dAMPH), while controlling for age and drug administration order (for Dataset 2 only). We then added a Sex Group $\times$ Drug type interaction to each flexible factorial model in SPM8 and tested for the presence of this interaction. We conducted T-tests between BP_{ND} from each drug session (placebo>dAMPH) as well as testing for the interaction with sex Females(placebo>dAMPH)>Males(placebo>dAMPH). We also conducted separate T-tests on male and female % BP_{ND} to assess differences in drug effects on BP_{ND} by Sex. In Dataset 1 we controlled for age while in Dataset 2 we controlled for age and drug administration order. Unthresholded statistical maps are available at: <https://neurovault.org/collections/4040/> (Dataset 1) & <https://neurovault.org/collections/4041/> (Dataset 2). For our ROI data, we compared placebo and dAMPH BP_{ND} by sex using a repeated measures ANOVA, controlling for age and drug administration order (Dataset 2), as needed. We also conducted T-tests on our ROI data, comparing males to

females on % BP_{ND}. For the voxelwise analyses, visualization p was set at <0.001 (voxel extent threshold=20) and only voxels meeting pFDR<0.05 at the cluster and/or peak level were considered significant. The raw participant data containing BP_{ND} values (from placebo and dAMPH session and calculated % BP_{ND}) from our *a priori* ROIs (including bilateral and unilateral striatal ROIs), dataset label, birth control and menopausal status of female subjects, age, sex, plasma estradiol levels, and subjective response ratings (Feel, Like, High, Want More) to the dAMPH are available on OSF: <https://osf.io/24zxk/>.

Results

First, we tested whether males and females from both datasets were well matched in terms of age, personality, ethnic distribution, injected dose of [¹⁸F]fallypride (mCi, volume (ml) injected) for each visit, and dAMPH dosage received. Impulsivity (Barratt Impulsiveness Scale) and novelty seeking (Tridimensional Personality Inventory – Novelty Seeking) were well matched across males and females in both datasets. Though Dataset 2 participants (mean age: 41.36±15.13) were older than Dataset 1 (mean age 22.38±3.10; $t(74)=7.18$, $p<0.001$), males and females within each dataset were well matched on age. Average age and ethnic distribution between males and females was similar within datasets (see Table 1). There were no differences in dAMPH dose by sex in either Dataset 1 ($t(32)=0.28$, $p=0.78$) or Dataset 2 ($t(40)=1.81$, $p=0.08$). Across both datasets, the average dAMPH dose was 0.438±0.015 mg/kg for females and 0.433±0.016 mg/kg for males. Also, we found no main effect of Drug administration session or Sex or Drug session × Sex interaction on injected dose of [¹⁸F]fallypride in Dataset 1 (max $F(1,32)=3.37$, min $p=0.076$, Drug session effect on injected volume) nor Dataset 2 (max $F(1,40)=3.92$, min $p=0.055$, Sex group effect on injected volume). Supplementary Table 2 reports the average injected dose (in mCi) and volume (in ml) of [¹⁸F]fallypride administered by Dataset, sex group, and drug administration session.

Dopamine Release

In our flexible factorial voxelwise analyses, we identified large areas of significant decrease in BP_{ND} on dAMPH relative to placebo with Dataset 1 displaying a large striatal cluster ($k=5,004$, pFDR<0.001, max $T=10.32$) as well as a medial thalamic cluster ($k=147$, pFDR=0.001, max $T=5.19$) and Dataset 2 displaying a single large striatal cluster ($k=1,871$, pFDR<0.001, max $T=7.25$) where placebo>dAMPH BP_{ND} (Supplementary Figure 2). However, we failed to detect a significant Drug administration session × Sex group effect on BP_{ND} in either Dataset. Similar null results were observed when we tested for Sex group differences in % BP_{ND} maps at a voxelwise level (see unthresholded SPM T-maps for Dataset 1: <https://neurovault.org/collections/3805/> and Dataset 2: <https://neurovault.org/collections/4124/>). We also tested for a significant Drug administration session × Sex group effect on BP_{ND} only in the voxels found to display a drug effect on BP_{ND} within each dataset (masking within the drug effect voxels). There was still no significant Drug administration session × Sex group effect on BP_{ND} in either dataset using these more restrictive analyses.

In Dataset 1, our ROI-based ANOVAs with Drug administration as a within subject measure and Sex group as a between subject measure found significant effects of drug on BP_{ND} in right pallidum ($F(1,32)=24.374$, $p<0.001$), bilateral VS ($F(1,32)=24.374$, $p<0.001$), bilateral caudate ($F(1,32)=26.331$, $p<0.001$), and bilateral putamen ($F(1,32)=99.215$, $p<0.001$) with a smaller but non-significant effect in right IFG ($F(1,32)=2.964$, $p=0.095$). There was no significant main effect of Sex nor a Sex $\times$ Drug interaction in any of the anatomically-defined ROIs (max $F(1,32)=2.014$, min $p=0.166$ in bilateral putamen). In Dataset 2, our ROI-based ANOVAs with Drug administration as a within subject measure, Sex group as a between subject measure and age and drug administration order as covariates found a significant main effect of Drug (placebo>dAMPH BP_{ND}) in right pallidum ($F(1,38)=5.98$, $p=0.019$), bilateral VS ($F(1,38)=4.75$, $p=0.036$), and bilateral putamen ($F(1,38)=8.19$, $p=0.007$) with a smaller but non-significant effect in bilateral caudate ($F(1,38)=2.84$, $p=0.10$). There was no significant main effect of Sex on BP_{ND} in the anatomically-defined ROIs (max $F(1,38)=1.81$, $p=0.19$ in right IFG). Furthermore, no ROI displayed a significant Sex $\times$ Drug interaction (max $F(1,38)=1.28$, min $p=0.27$ in bilateral VS) in Dataset 2.

We also tested for an interaction between Age group (young adults, aged 20–30; middle-aged adults, aged 50–65), Drug session, and Sex on BP_{ND} in these ROIs in Dataset 2. We found a significant Drug $\times$ Sex $\times$ Age group interaction in bilateral VS ($F(1,37)=9.10$, $p=0.005$) and right pallidum ($F(1,37)=8.34$, $p=0.006$) with a smaller but non-significant Drug $\times$ Sex $\times$ Age group interaction in right IFG BP_{ND} ($F(1,37)=3.94$, $p=0.055$). In both the bilateral VS and right pallidum, male young adults displayed significantly higher % BP_{ND} (VS: $15.5\pm 8.7\%$; right pallidum: $11.6\pm 6.1\%$) compared to female young adults (VS: $0.02\pm 17.5\%$; right pallidum: $1.3\pm 9.3\%$; $t(18)=2.50$, $p=0.022$ and $t(18)=2.94$, $p=0.009$, respectively). Female middle-aged adults showed non-significantly higher bilateral VS % BP_{ND} ($10.7\pm 7.6\%$) relative to male middle-aged adults (% BP_{ND}= $4.3\pm 9.3\%$; $t(20)=1.74$, $p=0.097$) while the sex difference in right pallidum % BP_{ND} in the middle-aged group (females: $5.9\pm 14.2\%$; males: $0.73\pm 11.6\%$) was non-significant ($t(20)=0.95$, $p=0.36$). There was no Drug $\times$ Sex $\times$ Age group interaction in bilateral caudate ($F(1,37)=1.26$, $p=0.27$) or putamen ($F(1,37)=0.03$, $p=0.87$).

Given the observed Drug $\times$ Sex $\times$ Age group interaction in the ROI data for Dataset 2, we reran the flexible factorial SPM analysis explicitly looking for Drug $\times$ Sex effects on BP_{ND} in the younger age group, which was the age group showing more evidence of a sex effect. In Dataset 2 young adults there were 2 distinct clusters showing a significant Drug $\times$ Sex effect on BP_{ND}: 1) a right ventral striatal/pallidum cluster (MNI coordinates: 20, 2, -2) showed significantly higher Male (Placebo>dAMPH BP_{ND}) effects relative to Females ($T=5.89$, $k(\text{cluster size})=260$, $p\text{FDR}<0.001$ cluster level); 2) a narrow focus near the boundary of the dorsal striatum, insula and neighboring white matter (MNI coordinates: 22, 16, 12) showed significantly higher Female (Placebo>dAMPH BP_{ND}) effects relative to Males ($T=4.14$, $k=136$, $p\text{FDR}=0.003$ cluster level; see unthresholded T-maps: <https://neurovault.org/images/65821/>).

Given the emergence of a lateralized effect in the above voxelwise analysis in young adults from Dataset 2, we conducted exploratory ROI analyses using the right and left components of our caudate, putamen, and VS ROIs. We first tested for a Sex $\times$ Drug $\times$ Age group

interaction on BP_{ND} in Dataset 2 in each of these 6 ROIs (Bonferroni corrected significance set at $p < 0.00833$), controlling for drug administration order. While we found Sex $\times$ Drug $\times$ Age group effects in right caudate ($F(1, 37) = 7.804$, $p = 0.008$; $\eta^2 = 0.135$) and VS, only the right VS ($F(1, 37) = 23.768$, $p < 0.001$; $\eta^2 = 0.307$) interaction survived correction for multiple comparisons. A significant Sex $\times$ Drug $\times$ Age group effect was also observed in the *a priori* right pallidum ROI ($F(1, 37) = 8.344$, $p = 0.006$; $\eta^2 = 0.142$). A closer examination found that Dataset 2 young adult males had a larger change in BP_{ND} from placebo to dAMPH visits ($\% BP_{ND} = 23\%$; Cohen's d for drug effect on $BP_{ND} = 1.70$) relative to their female counterparts ($\% BP_{ND} = -0.039\%$; Cohen's d for drug effect on $BP_{ND} = -0.24$; Sex $\times$ Drug interaction: $F(1, 17) = 17.58$, $p = 0.001$; $\eta^2 = 0.438$). By contrast, the Sex $\times$ Drug interaction was not significant in the left VS ($F(1, 17) = 0.052$, $p = 0.82$; $\eta^2 = 0.003$). To test the reliability of the Sex $\times$ Drug effect observed in the right VS in Dataset 2, we ran a follow-up test on this ROI in Dataset 1 subjects who were similar in age to the young adults in Dataset 2. However, we observed no significant Sex $\times$ Drug effect in right VS in Dataset 1 ($F(1, 32) = 0.122$, $p = 0.729$; $\eta^2 = 0.002$). In Dataset 1, change in BP_{ND} from placebo to dAMPH visits was equivalent across males ($\% BP_{ND} = 6.49\%$; Cohen's d for drug effect on $BP_{ND} = 0.70$) and females ($\% BP_{ND} = 8.06\%$; Cohen's d for drug effect on $BP_{ND} = 0.82$).

Subjective Effects

Previously, we found relationships between $\% BP_{ND}$ and the subjective effect of Wanting More dAMPH in vmPFC, left insula, and right VS in Dataset 1 (Smith et al. 2016a). In Dataset 1, females had lower Drug Effects Questionnaire (Morean et al. 2013) ratings (max FEEL, LIKE, HIGH, and WANT MORE dAMPH-placebo from one of 5 timepoints from 60 minutes to 345 minutes post drug) than males (all $T_s < -2.28$, $p < 0.03$; see Supplementary Table 3). To rule out the possibility that subjective effect differences by sex in Dataset 1 obscured our ability to detect Sex $\times$ Drug effects on $\% BP_{ND}$, we reran the flexible factorial analysis in SPM8 controlling for WANT MORE max rating, given it was associated with $\% BP_{ND}$ in this dataset previously (Smith et al. 2016a). We still observed no significant clusters displaying a Sex $\times$ Drug effect on BP_{ND} in this voxelwise analysis.

We did not observe sex differences in DEQ subjective measures in either the full Dataset 2 (max $T = 1.05$, min $p = 0.30$ (Females > Males) for max WANT MORE rating) or when restricting Dataset 2 to young adults only (max $T = 2.10$, min $p = 0.05$ for max HIGH rating; all other $p_s > 0.20$; Table S3). Interestingly, if we compare young adults from Dataset 2 to Dataset 1 individuals, males from Dataset 1 showed enhance HIGH ratings (47.06 ± 24.52) relative to Dataset 2 young adults (20.40 ± 20.77 ; $t(24) = 2.85$, $p = 0.009$). In contrast, Dataset 2 young females: 55.30 ± 25.48 showed elevated WANT MORE ratings relative to Dataset 1 females: 19.00 ± 28.41 ($t(26) = 3.36$, $p = 0.002$). It is unlikely that subjective effect differences across young adult females explain our finding a Sex $\times$ Drug effect in Dataset 2 young adults but not Dataset 1 given that the DEQ WANT MORE effect runs counter to our observed drug effect on right VS $\% BP_{ND}$. Previously we had found a positive relationship between DEQ WANT MORE and right VS $\% BP_{ND}$ (Smith et al. 2016a). Females in Dataset 1, however, showed less WANT MORE effects but displayed a modest effect of dAMPH on right VS BP_{ND} ($\% BP_{ND} = 8.06\%$; Cohen's d for drug effect on $BP_{ND} = 0.82$) which was not observed in Dataset 2 young adult females ($\% BP_{ND} = -0.039\%$; Cohen's d

for drug effect on $BP_{ND}=-0.24$) despite them showing higher WANT MORE ratings than Dataset 1 females.

Hormone Effects

Given past data on estradiol's effect on dAMPH-induced dopamine release in rodents (Becker 1990; 1999), we further examined whether there were any differences in our female subject's response to dAMPH in relation to estradiol or birth control. In these data, women of childbearing potential were studied within the first 10 days of their menstrual cycle. In Dataset 1 females, plasma estradiol levels were 25.76 ± 16.56 pg/ml (placebo visit) and 38.56 ± 31.47 pg/ml (dAMPH visit) and progesterone levels were 0.56 ± 0.38 ng/ml (placebo visit) and 0.96 ± 1.83 ng/ml (dAMPH visit). In Dataset 2, plasma estradiol levels were 58.35 ± 46.37 pg/ml (dAMPH visit). Importantly, in Dataset 1 estradiol did not vary in women on hormonal birth control (21.90 ± 19.07 pg/ml) versus those that were naturally cycling (but studied within cycle days 1–10; 31.29 ± 11.19 pg/ml) during the placebo visit: $t(15)=1.16$, $p=0.26$. There was a significant but small difference in estradiol between the groups during their dAMPH visit: $t(16)=2.47$, $p=0.025$ (birth control group: 25.74 ± 24.72 pg/ml; naturally cycling group: 58.71 ± 31.83 pg/ml). In Dataset 2 estradiol did not vary in women on hormonal birth control (60.40 ± 51.07 pg/ml) versus those that were naturally cycling (but studied within cycle days 1–10; 56.71 ± 46.86 pg/ml): $t(10)=-0.13$, $p=0.90$ (data collected on dAMPH visit only).

In regression analyses, dAMPH session estradiol was not predictive of dAMPH-induced DA release (% BP_{ND}) in any of the *a priori* anatomical ROIs (max $r=-0.29$, min $p=0.13$ in right IFG, across all female participants but controlling for dataset). In Dataset 1, % change in estradiol from placebo to dAMPH session was not correlated with % BP_{ND} in any region (max $\rho=-0.37$, $p=0.147$ in bilateral VS).

In addition, exploratory analyses were performed to examine whether dAMPH-induced DA release differed based on use of hormonal birth control. We found birth control use in young adult females (age < 50; total $n=28$, 17 on birth control) did not lead to any significant differences in dAMPH-induced DA release in the *a priori* anatomical ROIs we tested here (max $F=3.05$, min $p=0.093$ in right IFG; controlling for subject age and Dataset). In addition, we found no evidence of sex differences in dAMPH-induced DA release in the *a priori* anatomical ROIs when comparing males ($n=26$) to females on or not on hormonal birth control (three groups, all age < 50; max $F=1.58$, min $p=0.22$ in bilateral putamen; controlling for subject age and Dataset). Finally, rerunning our flexible factorial SPM voxelwise analyses in each dataset comparing males to females on and off birth control separately (Dataset 1 & 2) or comparing postmenopausal females to age-matched males (Dataset 2) did not lead to the identification of any significant clusters showing a Sex $\times$ Drug interaction on BP_{ND} (see unthresholded SPM T-maps for Dataset 1: <https://neurovault.org/collections/4040/> and Dataset 2: <https://neurovault.org/collections/4041/>).

Discussion

Elucidation of sex differences in the responsivity of the DA system is important given that sex differences in addiction vulnerability have been previously speculated to reflect

dopaminergic differences (Becker and Hu 2008). The present data indicate that to the extent healthy males and females show differences in d-AMPH-induced DA release, these differences appear subtle, regionally specific, and inconsistent across samples. In one of our two studies, we observed greater DA release in the right ventral striatum/ventral pallidum region, with young adult men showing greater release than females. This result is partially consistent with a prior study by Munro et al. (2006), who observed greater d-AMPH-induced DA release in a bilateral VS ROI in men than women as measured with [^{11}C]raclopride (Munro et al. 2006). This is intriguing in that it would suggest an enhanced response in a region specifically associated with reward-motivational processes. However, although our results partially replicate the finding of Munro et al. (2006), caution is necessary in drawing conclusions about VS sex differences given that we did not see evidence of a similar effect in the left VS, or other striatal regions, and we failed to see evidence for a similar sex effect in the other dataset presented here. While there may be methodological variables that contribute to different findings across datasets and studies, the overall picture suggests that sex differences in DA release are subtle and are not robust enough to emerge consistently across typical modestly-powered PET studies.

A clearer conclusion can be made regarding the possibility of a heightened DA response in women. While, the small preliminary study by Riccardi et al. (2006) suggested that women have a greater response to d-AMPH than men in the pallidum and inferior frontal gyrus, this has not been replicated, and indeed across the two present studies, and the papers by Riccardi (2006) and Munro (2006), no studies have indicated a heightened striatal response in women relative to men within the striatum proper.

While the present data do not support a widespread difference in d-AMPH-induced DA release based on sex, they also do not rule out the possibility that other features of the DA system may show sex differences. Indeed, there is at least some evidence of sex differences in other components of DA signaling. Females have been reported to show greater DA synthesis capacity, especially in caudate, measured with ^{18}F -fluorodopa PET relative to males (Laakso et al. 2002). Women have also been reported to have higher striatal DAT availability than men (Mozley et al. 2001) and this might be particularly pronounced in Parkinson's Disease and age-related declines in DAT which have been suggested to be steeper in men (Lee et al. 2015). Furthermore, estradiol can inhibit DA uptake via the DAT in PC12 cells (Watson et al. 2006) while also being able to rapidly reverse DAT to increase extracellular DA levels (Alyea et al. 2008). In addition, a SPECT pilot study found that estrogen replacement therapy increased putamen DAT availability after 4–6 weeks of treatment (Gardiner et al. 2004). That said, our results suggest that those differences do not substantially impact the amount of DA release induced by oral d-AMPH, at least as assessed with [^{18}F]fallypride PET.

In interpreting our effects, it is worth considering whether issues of menstrual phase, menopausal status, and reproductive hormone levels might influence the results. One possibility for our lack of widespread consistent sex effects could be that differences in d-AMPH-induced DA release are more related to female hormone levels than strict male and female differences *per se*. Returning to previous d-AMPH-induced DA release PET studies, Munro et al (2006) excluded women on hormonal birth control and measured plasma

estradiol and progesterone levels in the 15 women in their study. They found no relationship between estradiol nor progesterone and baseline ^{11}C -raclopride BP_{ND} or DA release despite having 9 women in the follicular phase (estradiol: 59.63 ± 45.03 pg/ml; progesterone: 0.83 ± 0.48 ng/ml) and 6 in the luteal phase (estradiol: 118.41 ± 69.62 pg/ml; progesterone: 10.18 ± 7.12 ng/ml) of their menstrual cycle. Riccardi et al (2006) did not examine hormone levels in their participants.

In the two current datasets, women were either naturally cycling but studied in the first 10 days of their menstrual cycle (when estradiol and progesterone levels are low), on hormonal birth control, or postmenopausal (Dataset 2). Calculation of plasma estradiol measurements in both Datasets and progesterone (Dataset 1) confirmed that hormone levels were relatively low in our female sample. Therefore, the relatively low level of female-associated hormones could have impacted the results. However, Munro et al (2006) had a larger range in these hormone values in their female subjects and still observed no effect on dAMPH-induced DA release. Thus, at present, support that either estradiol or progesterone lead to a differential response is lacking.

The lack of consistently observable sex differences in dAMPH-induced DA release may be informed by the work of Alyea and Watson (Alyea et al. 2008; Alyea and Watson 2009; Watson et al. 2006) who demonstrate that estradiol at physiological levels can sequester DAT in intracellular compartments (Watson et al. 2006) *in vitro* where it would be inaccessible for dAMPH to act to release DA. Estradiol at physiological concentrations can also lead to DAT-specific DA efflux on its own (via actions at the estrogen receptor α , $\text{ER}\alpha$) in the same *in vitro* preparation (Alyea et al. 2008). In fact, $\text{ER}\alpha$ been shown to associate with DAT on the plasma membrane (Alyea and Watson 2009). If these *in vitro* relationships hold *in vivo*, the presence and relative level of $\text{ER}\alpha$ in a brain region (Osterlund et al. 2000) along with the level of estradiol may affect DA concentration. dAMPH would presumably increase synaptic DA levels further but this may be limited by the relative surface availability of DAT, which has also been shown to be influenced by estradiol (Watson et al. 2006). As such, there may be a combination of sex differences in DAT functioning that are not captured by, or may even mask, observable dAMPH-induced DA release.

Limitations

First, we contrasted BP_{ND} following dAMPH versus placebo as the index of DA release. The use of placebo (where there was an expectation of potentially receiving dAMPH given that participants were blind to drug administration) rather than a true baseline state means that our measure of DA release could have been reduced by dopamine release occurring due to expectations on the placebo day (de la Fuente-Fernandez et al. 2001; Lidstone et al. 2010; Scott et al. 2008). However, the blind study design utilized here has advantages of limiting the impact of expectancies as opposed to actual drug effects.

While our findings are strengthened by the fact that we tested for sex effects in two independent datasets, the sample sizes in these studies, like prior studies, are individually relatively small. Unfortunately, the cost and complexity of a two-visit PET study limits the sample size that can be collected. In addition, there could be more subtle or time-limited sex differences in DA release in the brain. In order to estimate BP_{ND} and DA release, dynamic

image acquisition is required over a time period through which the tracer reaches a pseudo-equilibrium state. In the case of [^{18}F]fallypride, this collection time is roughly 3.5 hours. Thus, our PET measure of DA release may not capture short, transient increases in DA. Such temporally specific measures, however, can only be collected invasively in animals using techniques such as fast-scan cyclic voltammetry (Walker et al. 2000). There remains the possibility, then, that there are sex differences in more transient periods of DA release in humans.

In addition, it should be noted that although [^{11}C]raclopride and [^{18}F]fallypride are sensitive to dopamine release, the overall sensitivity is relatively modest, with [^{11}C]raclopride being somewhat more sensitive than [^{18}F]fallypride (Morris and Yoder 2007). However, the overall effect of dAMPH on [^{18}F]fallypride binding was statistically significant, especially in striatum (see Supplementary Figure 2) and has been shown to be sensitive enough to detect associations with other individual differences such as subjective responses to dAMPH (Smith et al. 2016a), effort-based decision making (Treadway et al. 2012), and the effects of dAMPH on task switching (Samanez-Larkin et al. 2013).

The complexity of studying sex effects and naturally fluctuating sex hormones is compounded by issues of birth control use and the postmenopausal transition with aging. Our datasets presented here contained women in these groups. While studying these women is more representative of the broader human population, the variability they could have introduced in our analyses may have hindered our ability to detect sex effects here. Importantly, however, we found no evidence for birth control use or menopausal status effecting dAMPH-induced DA release in our data. While, our statistical power was weak to detect the effects of birth control or menopausal status, the lack of observable birth control or menopausal status effects in the present samples indicates that these variables cannot easily explain why we observed no difference in male and female dAMPH-induced DA release.

Additionally, in the data presented here, females were always run within the first 10 days (follicular phase) of their menstrual cycle when estradiol and progesterone are relatively low. It is possible that comparing females in the luteal phase of their menstrual cycle when hormone levels are higher would have led to the observation of sex differences. The work of Munro et al (2006), however, found no effect of cycle phase on dAMPH-induced DA release, albeit with a limited sample size ($n=9$ and 6 in follicular and luteal phase, respectively). This analysis was between and not within-subjects, however. Thus, there remains the possibility that dAMPH-induced DA release could vary across the menstrual cycle within individual women, especially given evidence that D2/3 receptor availability varies over the cycle in non-human primates (Czoty et al. 2009), but see (Nordstrom et al. 1998), which did not find effects in a small number of human females. Finally, there is evidence that female rats show greater and more rapid sensitization to the locomotor activating effects and demonstrate larger changes in striatal DA signaling in response to repeated amphetamine administration (Camp and Robinson 1988). While there is no experimental evidence confirming this in humans, there remains the possibility that females could show enhanced DA release after repeated dAMPH exposure when compared to males.

More work is needed to isolate precisely which aspects of DA functioning show sex differences in humans. However, the present findings indicate that these sex differences do not include a widespread, robust or generalizable difference in the level of DA release in response to dAMPH, at least within the early follicular phase, and possibly regardless of menstrual phase.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This work was supported by AG043458 (DHZ & GRS-L) and AG042596 (GRS-L) from the National Institute on Aging and DA019670 (DHZ), DA041157 (CTS), and DA036979 (LCD) from the National Institute on Drug Abuse.

References

- Alyea RA, Laurence SE, Kim SH, Katzenellenbogen BS, Katzenellenbogen JA, Watson CS (2008) The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. *Journal of neurochemistry* 106: 1525–33. [PubMed: 18489713]
- Alyea RA, Watson CS (2009) Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux. *BMC Neurosci* 10: 59. [PubMed: 19531209]
- Becker JB (1990) Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. *Neuroscience letters* 118: 169–71. [PubMed: 2125712]
- Becker JB (1999) Gender differences in dopaminergic function in striatum and nucleus accumbens. *Pharmacology, biochemistry, and behavior* 64: 803–12.
- Becker JB, Hu M (2008) Sex differences in drug abuse. *Frontiers in neuroendocrinology* 29: 36–47. [PubMed: 17904621]
- Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS, Baldwin RM, Schwartzman AN, Shelby ES, Smith CE, Kessler RM, Zald DH (2010) Dopaminergic network differences in human impulsivity. *Science* 329: 532. [PubMed: 20671181]
- Calipari ES, Juarez B, Morel C, Walker DM, Cahill ME, Ribeiro E, Roman-Ortiz C, Ramakrishnan C, Deisseroth K, Han MH, Nestler EJ (2017) Dopaminergic dynamics underlying sex-specific cocaine reward. *Nature communications* 8: 13877.
- Camp DM, Robinson TE (1988) Susceptibility to sensitization. I. Sex differences in the enduring effects of chronic D-amphetamine treatment on locomotion, stereotyped behavior and brain monoamines. *Behavioural brain research* 30: 55–68. [PubMed: 2458741]
- Cummings JA, Jagannathan L, Jackson LR, Becker JB (2014) Sex differences in the effects of estradiol in the nucleus accumbens and striatum on the response to cocaine: neurochemistry and behavior. *Drug and alcohol dependence* 135: 22–8. [PubMed: 24332790]
- Czoty PW, Riddick NV, Gage HD, Sandridge M, Nader SH, Garg S, Bounds M, Garg PK, Nader MA (2009) Effect of menstrual cycle phase on dopamine D2 receptor availability in female cynomolgus monkeys. *Neuropsychopharmacology* 34: 548–54. [PubMed: 18256593]
- de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. *Science* 293: 1164–6. [PubMed: 11498597]
- Dohrenwend BP, Dohrenwend BS (1976) Sex differences and psychiatric disorders. *AJS* 81: 1447–54. [PubMed: 1036869]
- Earls F (1987) Sex differences in psychiatric disorders: origins and developmental influences. *Psychiatric developments* 5: 1–23. [PubMed: 3601929]

- Evans SM, Haney M, Foltin RW (2002) The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. *Psychopharmacology* 159: 397–406. [PubMed: 11823892]
- First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, New York
- Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: A general linear approach. *Human brain mapping* 2: 189–210.
- Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, Newberg A, Battistini M (2004) Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. *Am J Geriatr Psychiatry* 12: 621–30. [PubMed: 15545330]
- Griffin ML, Weiss RD, Mirin SM, Lange U (1989) A comparison of male and female cocaine abusers. *Archives of general psychiatry* 46: 122–6. [PubMed: 2913971]
- Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *NeuroImage* 6: 279–87. [PubMed: 9417971]
- Ivanova T, Beyer C (2003) Estrogen regulates tyrosine hydroxylase expression in the neonate mouse midbrain. *Journal of neurobiology* 54: 638–47. [PubMed: 12555275]
- Jackson LR, Robinson TE, Becker JB (2006) Sex differences and hormonal influences on acquisition of cocaine self-administration in rats. *Neuropsychopharmacology* 31: 129–38. [PubMed: 15920500]
- Justice AJ, de Wit H (1999) Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. *Psychopharmacology* 145: 67–75. [PubMed: 10445374]
- Kosten TA, Gawin FH, Kosten TR, Rounsaville BJ (1993) Gender differences in cocaine use and treatment response. *Journal of substance abuse treatment* 10: 63–6. [PubMed: 8450576]
- Laakso A, Vilkmann H, Bergman J, Haaparanta M, Solin O, Syvalahti E, Salokangas RK, Hietala J (2002) Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. *Biological psychiatry* 52: 759–63. [PubMed: 12372667]
- Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. *NeuroImage* 4: 153–8. [PubMed: 9345505]
- Lee JJ, Ham JH, Lee PH, Sohn YH (2015) Gender Differences in Age-Related Striatal Dopamine Depletion in Parkinson's Disease. *J Mov Disord* 8: 130–5. [PubMed: 26413240]
- Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernandez R, Phillips AG, Stoessl AJ (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. *Archives of general psychiatry* 67: 857–65. [PubMed: 20679593]
- Lynch WJ (2008) Acquisition and maintenance of cocaine self-administration in adolescent rats: effects of sex and gonadal hormones. *Psychopharmacology* 197: 237–46. [PubMed: 18066534]
- Lynch WJ, Arizzi MN, Carroll ME (2000) Effects of sex and the estrous cycle on regulation of intravenously self-administered cocaine in rats. *Psychopharmacology* 152: 132–9. [PubMed: 11057516]
- Lynch WJ, Carroll ME (1999) Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats. *Psychopharmacology* 144: 77–82. [PubMed: 10379627]
- Lynch WJ, Roth ME, Mickelberg JL, Carroll ME (2001) Role of estrogen in the acquisition of intravenously self-administered cocaine in female rats. *Pharmacology, biochemistry, and behavior* 68: 641–6.
- Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. *NeuroImage* 19: 1233–9. [PubMed: 12880848]
- Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. *J Cereb Blood Flow Metab* 21: 1034–57. [PubMed: 11524609]

- Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS (2013) The drug effects questionnaire: psychometric support across three drug types. *Psychopharmacology* 227: 177–92. [PubMed: 23271193]
- Morris ED, Yoder KK (2007) Positron emission tomography displacement sensitivity: predicting binding potential change for positron emission tomography tracers based on their kinetic characteristics. *J Cereb Blood Flow Metab* 27: 606–17. [PubMed: 16788713]
- Mozley LH, Gur RC, Mozley PD, Gur RE (2001) Striatal dopamine transporters and cognitive functioning in healthy men and women. *The American journal of psychiatry* 158: 1492–9. [PubMed: 11532737]
- Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, Kuwabara H, Kumar A, Alexander M, Ye W, Wand GS (2006) Sex differences in striatal dopamine release in healthy adults. *Biological psychiatry* 59: 966–74. [PubMed: 16616726]
- Nordstrom AL, Olsson H, Halldin C (1998) A PET study of D2 dopamine receptor density at different phases of the menstrual cycle. *Psychiatry research* 83: 1–6. [PubMed: 9754700]
- Osterlund MK, Keller E, Hurd YL (2000) The human forebrain has discrete estrogen receptor alpha messenger RNA expression: high levels in the amygdaloid complex. *Neuroscience* 95: 333–42. [PubMed: 10658612]
- Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V (1995) Acute stimulatory effect of estradiol on striatal dopamine synthesis. *Journal of neurochemistry* 65: 1651–7. [PubMed: 7561861]
- Riccardi P, Zald D, Li R, Park S, Ansari MS, Dawant B, Anderson S, Woodward N, Schmidt D, Baldwin R, Kessler R (2006) Sex differences in amphetamine-induced displacement of [(18)F]fallypride in striatal and extrastriatal regions: a PET study. *The American journal of psychiatry* 163: 1639–41. [PubMed: 16946193]
- Robbins SJ, Ehrman RN, Childress AR, O'Brien CP (1999) Comparing levels of cocaine cue reactivity in male and female outpatients. *Drug and alcohol dependence* 53: 223–30. [PubMed: 10080048]
- Roberts DC, Bennett SA, Vickers GJ (1989) The estrous cycle affects cocaine self-administration on a progressive ratio schedule in rats. *Psychopharmacology* 98: 408–11. [PubMed: 2501818]
- Samanez-Larkin GR, Buckholtz JW, Cowan RL, Woodward ND, Li R, Ansari MS, Arrington CM, Baldwin RM, Smith CE, Treadway MT, Kessler RM, Zald DH (2013) A thalamocortico-striatal dopamine network for psychostimulant-enhanced human cognitive flexibility. *Biological psychiatry* 74: 99–105. [PubMed: 23273721]
- Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. *Archives of general psychiatry* 65: 220–31. [PubMed: 18250260]
- Seeman MV (1997) Psychopathology in women and men: focus on female hormones. *The American journal of psychiatry* 154: 1641–7. [PubMed: 9396940]
- Smith CT, Dang LC, Buckholtz JW, Tetreault AM, Cowan RL, Kessler RM, Zald DH (2017) The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum. *Translational psychiatry* 7: e1091. [PubMed: 28398340]
- Smith CT, Dang LC, Cowan RL, Kessler RM, Zald DH (2016a) Variability in paralimbic dopamine signaling correlates with subjective responses to d-amphetamine. *Neuropharmacology* 108: 394–402. [PubMed: 27174408]
- Smith CT, Weafer J, Cowan RL, Kessler RM, Palmer AA, de Wit H, Zald DH (2016b) Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiology. *Journal of psychopharmacology (Oxford, England)* 30: 330–43.
- Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. *NeuroImage* 23 Suppl 1: S208–19. [PubMed: 15501092]
- Treadway MT, Buckholtz JW, Cowan RL, Woodward ND, Li R, Ansari MS, Baldwin RM, Schwartzman AN, Kessler RM, Zald DH (2012) Dopaminergic mechanisms of individual differences in human effort-based decision-making. *J Neurosci* 32: 6170–6. [PubMed: 22553023]

- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage* 15: 273–89. [PubMed: 11771995]
- Vernaleken I, Peters L, Raptis M, Lin R, Buchholz HG, Zhou Y, Winz O, Rosch F, Bartenstein P, Wong DF, Schafer WM, Grunder G (2011) The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. *J Cereb Blood Flow Metab* 31: 1958–66. [PubMed: 21587267]
- Walker QD, Rooney MB, Wightman RM, Kuhn CM (2000) Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry. *Neuroscience* 95: 1061–70. [PubMed: 10682713]
- Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, Jakubas AA (2006) Estradiol effects on the dopamine transporter - protein levels, subcellular location, and function. *Journal of molecular signaling* 1: 5. [PubMed: 17224081]
- White TL, Justice AJ, de Wit H (2002) Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. *Pharmacology, biochemistry, and behavior* 73: 729–41.

Figure 1. % BP_{ND} does not vary by sex in *a priori* anatomical regions of interest.

% BP_{ND} calculated from dAMPH and placebo BP_{ND} data from the five anatomical ROIs ($\% \text{BP}_{\text{ND}} = (\text{placebo BP}_{\text{ND}} - \text{dAMPH BP}_{\text{ND}}) / (\text{placebo BP}_{\text{ND}}) \times 100\%$) are plotted by Dataset and participant sex. We observed no significant differences in BP_{ND} Change when comparing males to females in either Dataset. R, right; IFG, inferior frontal gyrus. Error bars represent standard error of the mean.

Table 1.
Demographics of Dataset 1 and 2 by sex.

Males and females were well matched by age and impulsivity and novelty seeking personality traits. BIS-11, Barratt Impulsiveness Scale; TPQ-NS, Tridimensional Personality Questionnaire-Novelty Seeking

Dataset 1	Males (n=16)	Females (n=18)	<i>T, p</i>
	<i>M</i> (std dev)	<i>M</i> (std dev)	
Age	21.75 (3.24)	22.94 (2.96)	1.12, 0.27
BIS-11	58.06 (11.67)	57.50 (9.70)	−0.83, 0.42
TPQ-NS	17.75 (4.96)	16.28 (5.38)	−0.15, 0.88
Ethnicity (% Caucasian)	81.3	88.9	$\chi^2=0.39$, $p=0.53$
Dataset 2	Males (n=21)	Females (n=21)	<i>T, p</i>
Age	42.48 (15.57)	40.24 (14.98)	−0.48, 0.64
BIS-11	56.19 (9.23)	58.43 (8.39)	0.82, 0.42
TPQ-NS	12.67 (4.87)	13.33 (4.79)	0.45, 0.66
Ethnicity (% Caucasian)	90.0	61.9	$\chi^2=1.87$, $p=0.17$

Table 2.
Effect of d-amphetamine on BP_{ND} signal relative to placebo across Datasets and sex groups.

Fallypride BP_{ND} after placebo (Plc) and dAMPH administration in males and females across the 2 Datasets reveal consistent, significant BP_{ND} decline after dAMPH across Datasets, regardless of participant sex.

ROI	Plc BPnd	dAMPH BPnd	Plc > dAMPH
	<i>M</i> (std dev)	<i>M</i> (std dev)	<i>T</i> , <i>p</i>
Dataset 1 Females (n=18)			
R IFG	0.64 (0.16)	0.62 (0.14)	1.00, 0.33
R Pallidum	18.64 (2.96)	17.23 (2.25)	3.83, 0.001
VS	18.37 (2.33)	16.94 (1.61)	3.90, 0.001
Caudate	21.64 (2.21)	20.41 (1.58)	4.57, <0.001
Putamen	24.92 (2.47)	22.23 (1.90)	8.24, <0.001
Dataset 2 Females (n=21)			
R IFG	0.75 (0.37)	0.63 (0.28)	3.48, 0.002
R Pallidum	16.96 (3.15)	16.23 (3.10)	1.76, 0.095
VS	16.13 (2.41)	15.14 (2.67)	1.92, 0.07
Caudate	18.76 (3.40)	18.48 (2.95)	0.95, 0.35
Putamen	22.92 (3.52)	21.55 (3.09)	3.43, 0.003
Dataset 1 Males (n=16)			
R IFG	0.59 (0.14)	0.56 (0.11)	1.37, 0.19
R Pallidum	18.87 (3.01)	17.75 (3.45)	3.19, 0.006
VS	18.17 (1.98)	16.86 (2.21)	3.77, 0.002
Caudate	20.48 (2.03)	19.77 (2.35)	2.70, 0.017
Putamen	24.62 (1.92)	22.61 (2.58)	5.92, <0.001
Dataset 2 Males (n=21)			
R IFG	0.61 (0.24)	0.54 (0.26)	3.05, 0.006
R Pallidum	16.98(2.99)	15.78 (2.11)	3.08, 0.006
VS	15.76 (2.55)	14.10 (1.94)	4.29, 0.001
Caudate	17.86 (3.17)	17.30 (2.72)	2.00, 0.059
Putamen	22.31 (2.91)	20.64 (2.87)	6.77, <0.001